|
1
|
Furfaro F, Ragaini E, Peyrin-Biroulet L
and Danese S: Novel therapies and approaches to inflammatory bowel
disease (IBD). J Clin Med. 11:43742022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Selvakumar B and Samsudin R: Intestinal
barrier dysfunction in inflammatory bowel disease: Pathophysiology
to precision therapeutics. Inflamm Bowel Dis. 31:450–3464. 2025.
View Article : Google Scholar
|
|
3
|
Marincola Smith P, Choksi YA, Markham NO,
Hanna DN, Zi J, Weaver CJ, Hamaamen JA, Lewis KB, Yang J, Liu Q, et
al: Colon epithelial cell TGFβ signaling modulates the expression
of tight junction proteins and barrier function in mice. Am J
Physiol Gastrointest Liver Physiol. 320:G936–G957. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rader AG, Cloherty APM, Patel KS,
Almandawi DDA, Perez-Vargas J, Wildenberg ME, Muncan V, Schreurs R,
Jean F and Ribeiro CMS: Autophagy-enhancing strategies to promote
intestinal viral resistance and mucosal barrier function in
SARS-CoV-2 infection. Autophagy Rep. 4:25142322025. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang R, Xie L, Jiang P, Hou Y, Li D and
Wang W: Metformin may improve intestinal mucosal barrier function
and help prevent and reverse colorectal cancer in mice. J Cancer.
16:3703–3711. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Esmail S and Manolson MF: Advances in
understanding N-glycosylation structure, function, and regulation
in health and disease. Eur J Cell Biol. 100:1511862021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Montag N, Gousis P and Wittmann J: The
emerging role of GlycoRNAs in immune regulation and recognition.
Immunol Lett. 276:1070482025. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Flynn RA, Pedram K, Malaker SA, Batista
PJ, Smith BAH, Johnson AG, George BM, Majzoub K, Villalta PW,
Carette JE, et al: Small RNAs are modified with N-glycans and
displayed on the surface of living cells. Cell. 188:44702025.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
He M, Zhou X and Wang X: Glycosylation:
Mechanisms, biological functions and clinical implications. Signal
Transduct Target Ther. 9:1942024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang G, Yuan J, Luo J, Ocansey DKW, Zhang
X, Qian H, Xu W and Mao F: Emerging role of protein modification in
inflammatory bowel disease. J Zhejiang Univ Sci B. 23:173–188.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kudelka MR, Stowell SR, Cummings RD and
Neish AS: Intestinal epithelial glycosylation in homeostasis and
gut microbiota interactions in IBD. Nat Rev Gastroenterol Hepatol.
17:597–617. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yao Y, Kim G, Shafer S, Chen Z, Kubo S, Ji
Y, Luo J, Yang W, Perner SP, Kanellopoulou C, et al: Mucus
sialylation determines intestinal host-commensal homeostasis. Cell.
185:1172–1188.e28. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fan Q, Li M, Zhao W, Zhang K, Li M and Li
W: Hyper α2,6-Sialylation promotes CD4+ T-Cell activation and
induces the occurrence of ulcerative colitis. Adv Sci (Weinh).
10:e23026072023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shu X, Li J, Chan UI, Su SM, Shi C, Zhang
X, An T, Xu J, Mo L, Liu J, et al: BRCA1 insufficiency induces a
hypersialylated acidic tumor microenvironment that promotes
metastasis and immunotherapy resistance. Cancer Res. 83:2614–2633.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fan TC, Yeo HL, Hung TH, Chang NC, Tang
YH, Yu J, Chen SH and Yu AL: ST3GAL1 regulates cancer cell
migration through crosstalk between EGFR and neuropilin-1
signaling. J Biol Chem. 301:1083682025. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hong Y, Walling BL, Kim HR, Serratelli WS,
Lozada JR, Sailer CJ, Amitrano AM, Lim K, Mongre RK, Kim KD, et al:
ST3GAL1 and βII-spectrin pathways control CAR T cell migration to
target tumors. Nat Immunol. 24:1007–1019. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tajadura-Ortega V, Gambardella G, Skinner
A, Halim A, Van Coillie J, Schjoldager KTG, Beatson R, Graham R,
Achkova D, Taylor-Papadimitriou J, et al: O-linked mucin-type
glycosylation regulates the transcriptional programme downstream of
EGFR. Glycobiology. 31:200–210. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zaro BW, Bateman LA and Pratt MR: Robust
in-gel fluorescence detection of mucin-type O-linked glycosylation.
Bioorg Med Chem Lett. 21:5062–5066. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Y, Wang L, Ocansey DKW, Wang B, Wang
L and Xu Z: Mucin-Type O-Glycans: Barrier, microbiota, and immune
anchors in inflammatory bowel disease. J Inflamm Res. 14:5939–5953.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bergstrom K, Shan X, Casero D, Batushansky
A, Lagishetty V, Jacobs JP, Hoover C, Kondo Y, Shao B, Gao L, et
al: Proximal colon-derived O-glycosylated mucus encapsulates and
modulates the microbiota. Science. 370:467–472. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao Z, Zheng W, Zhang L, Song W and Wang
T: Sialyltransferase ST3GAL1 promotes malignant progression in
glioma. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 41:308–317. 2025.(In
Chinese). PubMed/NCBI
|
|
22
|
Busch M, Kämpfer AAM and Schins RPF: An
inverted in vitro triple culture model of the healthy and inflamed
intestine: Adverse effects of polyethylene particles. Chemosphere.
284:1313452021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Busch M, Ramachandran H, Wahle T, Rossi A
and Schins RPF: Investigating the role of the NLRP3 inflammasome
pathway in acute intestinal inflammation: Use of THP-1 knockout
cell lines in an advanced triple culture model. Front Immunol.
13:8980392022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kämpfer AAM, Busch M, Büttner V, Bredeck
G, Stahlmecke B, Hellack B, Masson I, Sofranko A, Albrecht C and
Schins RPF: Model complexity as determining factor for in vitro
nanosafety studies: Effects of silver and titanium dioxide
nanomaterials in intestinal models. Small. 17:e20042232021.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Aske KC and Waugh CA: Expanding the 3R
principles: More rigour and transparency in research using animals.
EMBO Rep. 18:1490–1492. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Deng X, Shang L, Du M, Yuan L, Xiong L and
Xie X: Mechanism underlying the significant role of the
miR-4262/SIRT1 axis in children with inflammatory bowel disease.
Exp Ther Med. 20:2227–2235. 2020.PubMed/NCBI
|
|
27
|
Samak G, Chaudhry KK, Gangwar R, Narayanan
D, Jaggar JH and Rao R: Calcium/Ask1/MKK7/JNK2/c-Src signalling
cascade mediates disruption of intestinal epithelial tight
junctions by dextran sulfate sodium. Biochem J. 465:503–515. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pan Q, Tian Y, Li X, Ye J, Liu Y, Song L,
Yang Y, Zhu R, He Y, Chen L, et al: Enhanced membrane-tethered
mucin 3 (MUC3) expression by a tetrameric branched peptide with a
conserved TFLK motif inhibits bacteria adherence. J Biol Chem.
288:5407–5416. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Olsen J, Gerds TA, Seidelin JB, Csillag C,
Bjerrum JT, Troelsen JT and Nielsen OH: Diagnosis of ulcerative
colitis before onset of inflammation by multivariate modeling of
genome-wide gene expression data. Inflamm Bowel Dis. 15:1032–1038.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sandborn WJ, Feagan BG, Marano C, Zhang H,
Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch
W, et al: Subcutaneous golimumab induces clinical response and
remission in patients with moderate-to-severe ulcerative colitis.
Gastroenterology. 146:85–95. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fang K, Bruce M, Pattillo CB, Zhang S,
Stone R II, Clifford J and Kevil CG: Temporal genomewide expression
profiling of DSS colitis reveals novel inflammatory and
angiogenesis genes similar to ulcerative colitis. Physiol Genomics.
43:43–56. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xu W, Guo Y, Huang Z, Zhao H, Zhou M,
Huang Y, Wen D, Song J, Zhu Z, Sun M, et al: Small heat shock
protein CRYAB inhibits intestinal mucosal inflammatory responses
and protects barrier integrity through suppressing IKKβ activity.
Mucosal Immunol. 12:1291–1303. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fan J, Huang S, Cao C, Jin X and Su Y: The
roles of ST3Gal1-6 in cancer: Expression profiles and functional
implications. Carbohydr Res. 559:1097402025. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ma X, Li M, Wang X, Qi G, Wei L and Zhang
D: Sialylation in the gut: From mucosal protection to disease
pathogenesis. Carbohydr Polym. 343:1224712024. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Al Saoud R, Hamrouni A, Idris A, Mousa WK
and Abu Izneid T: Recent advances in the development of
sialyltransferase inhibitors to control cancer metastasis: A
comprehensive review. Biomed Pharmacother. 165:1150912023.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Perez S, Fu CW and Li WS:
Sialyltransferase inhibitors for the treatment of cancer
metastasis: Current challenges and future perspectives. Molecules.
26:56732021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Uslupehlivan M, Şener E and İzzetoğlu S:
Computational analysis of the structure, glycosylation and CMP
binding of human ST3GAL sialyltransferases. Carbohydr Res.
486:1078232019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hatano K, Miyamoto Y, Nonomura N and
Kaneda Y: Expression of gangliosides, GD1a, and sialyl
paragloboside is regulated by NF-κB-dependent transcriptional
control of α2,3-sialyltransferase I, II, and VI in human
castration-resistant prostate cancer cells. Int J Cancer.
129:1838–1847. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kelm M, Quiros M, Azcutia V, Boerner K,
Cummings RD, Nusrat A, Brazil JC and Parkos CA: Targeting
epithelium-expressed sialyl Lewis glycans improves colonic mucosal
wound healing and protects against colitis. JCI Insight.
5:e1358432020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Taniguchi M, Okumura R, Matsuzaki T,
Nakatani A, Sakaki K, Okamoto S, Ishibashi A, Tani H, Horikiri M,
Kobayashi N, et al: Sialylation shapes mucus architecture
inhibiting bacterial invasion in the colon. Mucosal Immunol.
16:624–641. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhao T, Liu S, Ma X, Shuai Y, He H, Guo T,
Huang W, Wang Q, Liu S, Wang Z, et al: Lycium barbarum
arabinogalactan alleviates intestinal mucosal damage in mice by
restoring intestinal microbes and mucin O-glycans. Carbohydr Polym.
330:1218822024. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kotlarz D: Mucus sialylation maintains the
peace in intestinal host microbe relations. Gastroenterology.
163:527–528. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sánchez-Martínez E, Garrido-Romero M and
Moreno FJ: Functional role of ST6GALNAC1-mediated sialylation of
mucins in preserving intestinal barrier integrity and ameliorating
inflammation. Allergy. 77:3697–3698. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Petit C, Rozières A, Boschetti G, Viret C,
Faure M, Nancey S and Duclaux-Loras R: Advances in understanding
intestinal homeostasis: Lessons from inflammatory bowel disease and
monogenic intestinal disorder pathogenesis. Int J Mol Sci.
26:61332025. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mizoguchi A: Animal models of inflammatory
bowel disease. Prog Mol Biol Transl Sci. 105:263–320. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Le NPK, Altenburger MJ and Lamy E:
Development of an Inflammation-triggered in vitro ‘Leaky Gut’ Model
using Caco-2/HT29-MTX-E12 combined with Macrophage-like THP-1 cells
or primary Human-derived macrophages. Int J Mol Sci. 24:74272023.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Weber L, Kuck K, Jürgenliemk G, Heilmann
J, Lipowicz B and Vissiennon C: Anti-Inflammatory and
Barrier-stabilising effects of myrrh, coffee charcoal and chamomile
flower Extract in a Co-Culture cell model of the intestinal mucosa.
Biomolecules. 10:10332020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ma L, Zhang X, Zhang C, Hou B and Zhao H:
FOSL1 knockdown ameliorates DSS-induced inflammation and barrier
damage in ulcerative colitis via MMP13 downregulation. Exp Ther
Med. 24:5512022. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Roselli M, Maruszak A, Grimaldi R,
Harthoorn L and Finamore A: Galactooligosaccharide treatment
alleviates DSS-induced colonic inflammation in Caco-2 cell model.
Front Nutr. 9:8629742022. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang Y, Wen R, Liu D, Zhang C, Wang ZA and
Du Y: Exploring effects of chitosan oligosaccharides on the
DSS-Induced intestinal barrier impairment in vitro and in vivo.
Molecules. 26:21992021. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
De Cecco F, Franceschelli S, Panella V,
Maggi MA, Bisti S, Bravo Nuevo A, D'Ardes D, Cipollone F and
Speranza L: Biological response of treatment with saffron petal
extract on Cytokine-induced oxidative stress and inflammation in
the Caco-2/Human leukemia monocytic Co-Culture model. Antioxidants
(Basel). 13:12572024. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Yin S, Yang H, Tao Y, Wei S, Li L, Liu M
and Li J: Artesunate ameliorates DSS-induced ulcerative colitis by
protecting intestinal barrier and inhibiting inflammatory response.
Inflammation. 43:765–776. 2020. View Article : Google Scholar : PubMed/NCBI
|
